EUVIMEDEUVIMED entdecken
Crossref

Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression

Alaina J Kessler, Rima Patel, Emily Jane Gallagher, Tianxiang Sheng, Damodara Rao Mendu, Amy Tiersten, Paula Klein, Aarti S Bhardwaj, Anupama Goel, Joseph A Sparano, Theresa Shao, Julie Fasano

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07439-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Alaina J Kessler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Lev…. Hauptthemen laut MEDLINE: Estradiol, Premenopause, Breast Neoplasms, Benzimidazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Approximately 15% of women who receive ovarian function suppression (OFS) as adjuvant treatment for high-risk, localized hormone receptor-positive (HR+) breast cancer may have inadequate estradiol suppression which can require therapeutic modification when used in combination with an aromatase inhibitor (AI). We previously reported that abemaciclib may interfere with the estradiol Abbott Alinity chemiluminescent microparticle immunoassay (CMIA) commonly used to monitor estradiol levels and suggested liquid chromatography-mass spectrometry (LC-MS/MS) is preferred in this setting. The aim of this study was to determine discrepancies in estradiol levels using CMIA compared to LC-MS/MS and subsequent treatment changes in a larger patient population. METHODS: We conducted a retrospective review of premenopausal women with early-stage HR+ breast cancer at our institution who received adjuvant OFS and abemaciclib with at least 1 CMIA estradiol level drawn during abemaciclib therapy from October 2021 to April 2023. RESULTS: Of the 22 women who met criteria for review, 20 (90.9%) had CMIA estradiol levels in the premenopausal range, of whom 9 also had estradiol measured by LC-MS/MS. All 9 women receiving OFS and abemaciclib with estradiol measurements by both methods had premenopausal range CMIA estradiol levels and postmenopausal range LC-MS/MS estradiol levels. Of the 20 patients with premenopausal estradiol levels by CMIA estradiol, treatment changes included increased OFS dosage or preparation (n = 7), change from AI to tamoxifen (n = 3), and surgical oophorectomy (n = 7). CONCLUSION: Our findings suggest the likely interference of abemaciclib with the Abbott Alinity immunoassay which may lead to unnecessary treatment changes. It is recommended that the LC-MS/MS assay be used when monitoring estradiol levels in patients receiving abemaciclib concurrently with OFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EstradiolPremenopauseBreast NeoplasmsBenzimidazolesHumansFemaleAdultRetrospective StudiesMiddle AgedTandem Mass SpectrometryAminopyridinesChromatography, LiquidAromatase InhibitorsChemotherapy, AdjuvantOvary

Stichwörter der Autor:innen

AbemaciclibBreast cancerOvarian function suppressionPremenopausal

Substanzen

EstradiolabemaciclibBenzimidazolesAminopyridinesAromatase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. alaina.kessler@mountsinai.org.
  • Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
  • Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Förderung

  • NIH HHS
  • National Institutes of Health
  • Pfizer
  • Novartis Pharmaceuticals Corporation
  • Eli Lilly and Company
  • Breast Cancer Research Foundation
  • Susan G. Komen for the Cure
  • V Foundation

Zitieren

APA

Kessler, A. J., Patel, R., Gallagher, E. J., Sheng, T., Mendu, D. R., Tiersten, A., Klein, P., Bhardwaj, A. S., Goel, A., Sparano, J. A., Shao, T., & Fasano, J. (2024). Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07439-y

Vancouver

Kessler AJ, Patel R, Gallagher EJ, Sheng T, Mendu DR, Tiersten A, et al. Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07439-y

BibTeX
@article{Kessler2024,
  author = {Kessler, Alaina J and Patel, Rima and Gallagher, Emily Jane and Sheng, Tianxiang and Mendu, Damodara Rao and Tiersten, Amy and Klein, Paula and Bhardwaj, Aarti S and Goel, Anupama and Sparano, Joseph A and Shao, Theresa and Fasano, Julie},
  title = {Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07439-y}
}
Kostenlos starten →